Evidence map›Paper›PMID 37395796›Full record

ArticleOncotarget2023

Transformation of immunosuppressive mtKRAS tumors into immunostimulatory tumors by Nerofe and Doxorubicin.

Joel Ohana, Uziel Sandler, Orly Devary, Yoram Devary

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Joel OhanaImmune System Key (ISK) Ltd., Jerusalem 9746009, Israel.
Uziel SandlerImmune System Key (ISK) Ltd., Jerusalem 9746009, Israel.
Orly DevaryImmune System Key (ISK) Ltd., Jerusalem 9746009, Israel.
Yoram DevaryImmune System Key (ISK) Ltd., Jerusalem 9746009, Israel.
Jerusalem College of Technology · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Members of the rat sarcoma viral oncogene (RAS) subfamily KRAS are frequently mutated oncogenes in human cancers and have been identified in pancreatic ductal, colorectal, and lung adenocarcinomas. In this study, we show that a derivative of the hormone peptide Tumor Cell Apoptosis Factor (TCApF), Nerofe

Indexed as

MicroRNAsProto-Oncogene Proteins p21(ras)Cell Line, TumorDoxorubicinHumansImmunosuppressive AgentsPeptidesDoxorubicinImmunosuppressive AgentsMicroRNAsMIRN217 microRNA, humanPeptidesProto-Oncogene Proteins p21(ras)tumor-cells apoptosis factor, humanapoptosisColorectal cancerendoplasmic reticulum stresshormone peptideKRAS

Identifiers

PMID37395796
PMCPMC10317071
OpenAlexW4382795049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.